🟢 IDEXX is trading 18% up today after beating Q3 estimates and raising 2026 guidance

IDEXX is trading at $650.87, up 18.08%, after beating Q3 estimates and raising its 2026 outlook.

• Third-quarter revenue was $1.21 billion and adjusted EPS was $3.96, topping estimates of $1.19 billion and $3.72.
• IDEXX raised 2026 revenue guidance to $4.741–$4.767 billion and EPS guidance to $14.96–$15.16, citing strong diagnostics performance.
• CAG Diagnostics recurring revenue grew 11% organically, while the company lowered its full-year operating-margin outlook.